Effect of N-acetylcysteine on hydrogen sulfide in chronic kidney disease - Effect of NAC on H2S in CKD

• Conditions: Chronic kidney diseaseEnd stage renal disease; MedDRA version: 12.1Level: LLTClassification code 10064848Term: Chronic kidney disease; MedDRA version: 12.1Level: LLTClassification code 10014646Term: End stage renal disease (ESRD)

• Registration Number: EUCTR2010-022994-32-NL
• Lead Sponsor: MC Utrecht

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Study Start: 2010-11-08
• Last Update Posted: 19 March 2012

Recruitment & Eligibility

• Status: Authorised-recruitment may be ongoing or finished
• Sex: All
• Target Recruitment: Not specified

Inclusion Criteria

Healthy volunteers:
-Adult (> 18 years and older)
-Healthy, as assessed by medical history, blood pressure, plasma
creatinine, and urine dipstick
-No medication use

CKD patient:
-Adult (> 18 years and older)
-CKD stage 3-4 (GFR 15-60 ml/min)

Hemodialysis patient:
-Adult (> 18 years and older)
-Hemodialysis patient

Peritoneal dialysis patient:
-Adult (> 18 years and older)
-Peritoneal dialysis patient

Are the trial subjects under 18? no
Number of subjects for this age range:
F.1.2 Adults (18-64 years) yes
F.1.2.1 Number of subjects for this age range
F.1.3 Elderly (>=65 years) yes
F.1.3.1 Number of subjects for this age range

Exclusion Criteria

-Unable to give informed consent
-Hypersensitivity to NAC
-Pregnancy

Study & Design

• Study Type: Interventional clinical trial of medicinal product
• Study Design: Not specified